Review article
Open access
Under a Creative Commons license
Review ArticleAdvancements in therapeutic peptides: Shaping the future of cancer treatment
Author links open overlay panel, , , ,
Abstract
In the evolving landscape of cancer treatment, therapeutic peptides are assuming to play an increasingly vital role. Although the number of peptide drugs available for clinical cancer treatment is currently limited, extensive preclinical research is underway, presenting a promising trajectory for the future. The collaborative efforts of natural anti-cancer peptides (ACPs) and synthetic ACPs, propelled by advancements in molecular biology and peptide chemistry, are steering remarkable progress in this domain. We explores the intricate mechanisms underlying the anti-cancer effects of these peptides. The exploration of innovative strategies, including cancer immunotherapy and advanced drug delivery systems, is likely to contribute to the increasing presenceuse of peptide drugs in clinical cancer care. Furthermore, we delve into the potential implications and challenges associated with this anticipated shift, emphasizing the need for continued research and development to unlock the full therapeutic potential of peptide drugs in cancer treatment.
Keywords
Anti-cancer peptides
;
Mechanism
;
Immunotherapy
;
Drug delivery systems
;
Clinical therapeutics
Abbreviations
AAs,
Amino Acids
;
ACPs,
Anti-Cancer Peptides
;
AHX,
6-aminohexanoic acid
;
CD,
Circular Dichroism
;
CD13,
Mammalian Aminopeptidase N
;
CD4+ T cells,
Cluster of Differentiation 4 Positive T cells
;
CD8+ T cells,
Cluster of Differentiation 8 Positive T cells
;
CL,
Leucine-zipper-like motif
;
CPPs,
Cell Penetrating Peptides
;
CTLA-4,
Cytotoxic T-Lymphocyte Antigen 4
;
DBAASP,
Database of Antimicrobial Activity and Structure of Peptides
;
DDS,
Drug Delivery System
;
EBRT,
External Beam Radiotherapy
;
GA,
Genetic Algorithms
;
GH,
Growth Hormone
;
GLP-1,
Glucagon-Like Peptide-1
;
GnRH,
Gonadotropin-Releasing Hormone
;
HTVS,
High-Throughput Virtual Screening
;
ICD,
Immunogenic Cell Death
;
IL-1,
Interleukin-1
;
IL-2,
Interleukin-2
;
IL-6,
Interleukin-6
;
IL-10,
Interleukin-10
;
LJPs,
Laminaria japonica Peptides
;
MHC I,
Major Histocompatibility Complex Class I
;
MHC II,
Major Histocompatibility Complex Class II
;
MMP9,
Matrix Metalloproteinase 9
;
NDVs,
Numerical Descriptive Vectors
;
PD-1,
Programmed Cell Death Protein 1
;
PD-L1,
Programmed Cell Death Ligand 1
;
PDGF,
Platelet-Derived Growth Factor
;
PEG,
Polyethylene Glycol
;
PPIs,
Protein-Protein Interactions
;
QSAR,
Quantitative Structure-Activity Relationship
;
SPR,
Surface Plasmon Resonance
;
TAMs,
Tumor-Associated Macrophages
;
TANs,
Tumor-Associated Neutrophils
;
Treg cells,
T Regulatory cells
;
TNF-α,
Tumor Necrosis Factor Alpha
;
VEGF,
Vascular Endothelial Growth Factor
;
VEGFR2,
Vascular Endothelial Growth Factor Receptor 2
;
VHL,
Von Hippel-Lindau
;
WT1,
Wilms' Tumor 1
;
CTLA-4,
cytotoxic T-lymphocyte-associated protein 4
;
IFA,
Incomplete Freund's Adjuvant
Data availability
No data was used for the research described in the article.